Biovie is trading 9.8% up at $1.60 in pre-market on October 5; the available evidence does not establish a specific catalyst. - Recent reported company news includes September Long COVID trial results and a September update on Parkinson’s Phase 3 planning; searches found no fresh October 5 announcement directly explaining the move. - Supplied broader market indicators are nearly flat and mixed, so they do not clearly explain the rise. The move may reflect trading activity without a confirmed news trigger.